Switching From Semaglutide to Tirzepatide: What to Expect, Dose by Dose

Written by Dr. Diana Munteanu. Updated October 24, 2026.

Switching from semaglutide to tirzepatide is common, usually safe, and often worth it if semaglutide has stalled: in the only head-to-head trial, people on tirzepatide lost about 20% of their body weight versus about 14% on semaglutide. The practical surprise is that there is no dose conversion chart. Whatever semaglutide dose you are on, tirzepatide starts at its own lowest dose, 2.5 mg, for four weeks, and your doctor decides how fast to climb from there. Most people switch the week their next semaglutide injection would have been due, with no washout.

This guide covers why people switch, what the trials say about effectiveness, exactly what happens to your dose, which side effects to expect in the transition weeks, what it costs in October 2026, and when switching is not the right move.

The GIP piece is what tirzepatide adds. GIP appears to boost appetite suppression, improve how fat tissue handles energy and, counterintuitively, reduce nausea from GLP-1, which lets doctors push to doses that produce more weight loss. Semaglutide's advantage is a deeper evidence base, including the SELECT heart-outcome trial and the MASH approval.

For weight, yes, on average. SURMOUNT-5 randomized 751 adults with obesity and no diabetes to the highest tolerated dose of either drug for 72 weeks. Tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide 2.4 mg, and 31.6% of tirzepatide patients lost at least 25% of their weight versus 16.1% on semaglutide. In the diabetes trial SURPASS-2, tirzepatide also lowered A1C more than semaglutide 1 mg and took off more weight at every dose.

Two caveats. SURMOUNT-5 compared tirzepatide with Wegovy 2.4 mg; the newer 7.2 mg Wegovy HD dose produced about 20.7% in its own trial and has not been tested head to head. And averages hide individuals: some people respond better to semaglutide, and about one in seven respond poorly to either.

Yes. Both drugs are weekly injections that act on overlapping pathways, and switching between GLP-1-class drugs is routine in clinical practice. Neither label requires a washout period, and there is no known dangerous interaction, as long as you do not take both in the same week. The main requirements are a prescription for tirzepatide, a plan for the dose, and awareness that your body has to adjust to a new molecule even though it is doing a similar job.

People switch the other way too, most often for semaglutide's proven cardiovascular benefit or because the Wegovy pill suits them better than injections. Switching is not a one-way upgrade.

This is the question people ask most, and the answer is that the milligrams do not translate. Semaglutide 2.4 mg and tirzepatide 15 mg are both "top doses," but 2.4 mg of one is not equivalent to any dose of the other; they are different molecules with different potencies per milligram. The Zepbound and Mounjaro labels give one starting dose, 2.5 mg, for all new patients, and the labels for both drugs say nothing about transferring from a prior GLP-1 dose.

Because tirzepatide 2.5 mg is weaker than the semaglutide dose most switchers are leaving, hunger can creep back and the scale may stall for the first month. This is expected, not a sign the switch failed; the weight effect builds from 5 mg onward. Our semaglutide dosage chart shows the ladder you are leaving.

Even if you had no side effects left on semaglutide, starting a new GLP-1-class drug restarts the adjustment period for your stomach. Expect some of the following in the first two to six weeks and after each dose increase:

Serious risks are the same class risks: pancreatitis, gallbladder disease, severe gastrointestinal problems, and, for people on insulin or sulfonylureas, low blood sugar. Tirzepatide carries the same boxed warning about thyroid C-cell tumors in rodents. The practical rules that helped on semaglutide, smaller meals, less fat and alcohol, plenty of fluids and protein, apply again. See our side effects page and, if you are worried about body composition, does semaglutide cause muscle loss.

Insurance is the bigger variable: many plans cover one drug and not the other, or cover them for diabetes but not for weight. Call your plan before switching, and ask about prior authorization. Our semaglutide cost guide explains the options.

Switching the other way, from an older weekly GLP-1 such as dulaglutide to semaglutide, follows a similar logic and is covered in Trulicity vs Ozempic, including the usual one-week gap and starting-dose choices.

Switching from semaglutide to tirzepatide is a reasonable, well-trodden step for people who have stalled or responded poorly on semaglutide, and on average it delivers more weight loss. The switch itself is simple: finish semaglutide, start tirzepatide at 2.5 mg a week later, climb slowly, and expect a few weeks of readjustment. Do not expect your old dose to carry over, do not take both drugs, and do not switch away from semaglutide's heart or liver protection without a conversation about why. For what semaglutide does well on its own, read semaglutide for weight loss; for what comes next after both drugs, see retatrutide vs semaglutide.

This article is for general information and is not medical advice. Never switch, combine or change the dose of these medicines without your prescriber.